UroGen: Rises as cancer drug shows promise in interim data

UroGen Pharma

03/04/2020 16:20

** U.S.-listed shares of drug developer  URGN.O  rise 8.6%
to $18.46 - among top pct gainers across U.S. exchanges
    ** Co reported positive interim data from a mid-stage trial
testing its drug, UGN-102, to treat non-muscle invasive bladder
cancer  urn:newsml:reuters.com:*:nBw5w5N0ja
    ** Says trial demonstrated a complete response rate of 65%
at three months following onset of treatment
    ** In this subset of patients, 97% and 85% of patients
remained free of disease at six and nine months follow-up,
respectively - URGN
    ** As of last close, URGN almost halved YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))